Skip to main content

Exploring the use of novel and conventional therapies to combat metastatic cancer

1 June 2016

Cardiff China Medical Research Collaborative senior staff
Cardiff China Medical Research Collaborative senior staff

Professor Wen Jiang, Dr Andrew Sanders and Dr Lin Ye from the Cardiff China Medical Research Collaborative (CCMRC) highlight the work being done to combat metastatic cancer and develop new treatments in the May issue of Adjacent Government magazine.

Cancer is a serious issue world-wide that results in substantial morbidity and mortality for affected patients. Dissemination of cancer cells to secondary locations, through metastatic spread is tightly linked to patient outcomes and treatment options.

In this article, CCMRC’s researchers explain why there are limited options available for the treatment of most types of metastatic cancer and consider the potential of novel therapies, such as the use of low toxicity, well tolerated compounds found in phytochemicals. The team suggest that therapies, or combinations of novel and conventional therapies may hold the key to the development of anti-metastatic therapies and aid in the management of the disease.

CCMRC's article can be found in the May issue of Adjacent Government on page 75

Adjacent Government is a monthly magazine which provides a platform for policy makers, experts, and front-line figures to highlight new projects, discuss and debate current challenges and communicate instances of best practice.

Share this story